Metagame cover art

Metagame

Metagame

Written by: Grep News | Alex Rock
Listen for free

Metagame is a data-driven podcast for venture capitalists, private equity professionals, and institutional allocators who need to understand what global capital deployment actually means for portfolio strategy. Every quarter, we analyze every SEC Form D filing and decode the patterns, so you can see around the corner. We track market forces at work and produce info-packed 10 minute episodes, so you can keep moving money. No founder interviews. No prediction tracking. Just patterns in the data delivered with the energy of our AI host, Alex Rock. New episodes drop on Tuesdays and Thursdays. Subscribe if your job depends on knowing what just happened and why it matters. Available on YouTube, Spotify, or Apple Podcasts. Metagame is for information and entertainment only. Nothing on this show is investment advice. https://grep.news/podcast/metagame© 2026 Tamez Labs. All rights reserved. Economics Personal Finance Politics & Government
Episodes
  • Beyond xAI the 2 billion semiconductor bet nobody covered

    Beyond xAI the 2 billion semiconductor bet nobody covered
    May 21 2026
    While everyone obsessed over OpenAI's $122 billion raise, $4.3 billion quietly flowed through SEC filings into eight companies nobody talked about—inference chips, data infrastructure, AI hiring platforms—the actual plumbing that makes frontier AI work. Marvell raised $2 billion for custom silicon, MatX got $530 million for inference optimization, and Mercor landed $330 million targeting the skills gap that's killing 95% of enterprise AI pilots. The mega-rounds got the headlines but the SEC Form D tape just showed you what smart money is actually buying: the companies OpenAI can't operate without.
    Show More Show Less
    9 mins
  • Pharma deal flow collapsed 62 percent while AI startups hide in plain sight

    Pharma deal flow collapsed 62 percent while AI startups hide in plain sight
    May 19 2026
    Pharma deal flow didn't collapse 62.5 percent last quarter — it just stopped filing as pharma. AI-native drug discovery companies like Recursion and Insitro are filing under "Other Technology" because their value lives in computational platforms, not clinical pipelines, which means healthcare funds tracking SEC codes are literally missing deals before they hit the committee. Total healthcare-adjacent deal count stayed completely flat at 74 deals, but if your allocation strategy runs on sector labels instead of manual tagging, you're benchmarking against a category that no longer describes where the actual capital is flowing.
    Show More Show Less
    9 mins
  • New York venture deals now outpace entire Bay Area combined

    New York venture deals now outpace entire Bay Area combined
    May 14 2026
    NYC just closed 119 venture deals worth $70.4 billion in Q1 while San Francisco proper did 39 deals at $4.7 billion, and somehow the entire VC world is still pretending you have to be in the Bay to access deals. The gap isn't even close—New York has a 65% deal-count advantage, and here's the kicker: Atlanta matched San Francisco at 39 deals each. Everyone's optimizing for geographic proximity to AI labs while SEC Form D data shows the actual repeatable deal velocity is happening 3,000 miles east, but nobody's updated the conference talking points yet.
    Show More Show Less
    8 mins
adbl_web_anon_alc_button_suppression_c
No reviews yet